



Biotech Daily

Tuesday April 2, 2024

Daily news on ASX-listed biotechnology companies

- * MARCH BDI-40 RECORD HIGH - UP 3%, ASX200 UP 3%, BIG CAPS UP 2.5%
- * TODAY: ASX DOWN, BIOTECH EVEN: MESOBLAST UP 71%; ALCIDION DOWN 8%
- * AEGROS TO RAISE \$100m FOR HYPERIMMUNE PLASMA FRACTIONATION
- * IMRICOR PLACES \$6.5m RIGHTS OFFER SHORTFALL; TOTAL \$15m
- * RESONANCE TO PAY \$8m FOR TRIALSWEST
- * COGSTATE AMENDS EISAI LICENCE
- * CENTENARY WINS \$200k OVARIAN CANCER RESEARCH GRANT
- * QUEENSLAND UNI: 'AMYLOID PLAQUE NOT ALZHEIMER'S TARGET, IN MICE'
- * ARTRYA SIGNS SALIX CONTRACT WITH CARDIAC CENTRE NSW
- * CARTHERICS, TICAROS CLIP-CAR-NK RESEARCH DEAL
- * PERCHERON ENROLS 76% OF PHASE IIb ATL1102 DUCHENNE TRIAL
- * CARDIEX COMPLETES BIOMARKER STUDY; US CONNEQT PATENT
- * BCAL WINS AUSTRALIAN BREASTEST, BCAL DX TRADEMARKS
- * PHARMAUST RETRACTS MEDIA FINANCIAL FORECASTS
- * MGC BECOMES 'ARGENT BIOPHARMA' TOMORROW
- * ASX SUSPENDS IMAGION, OSTEOPORE ON LATE REPORTS
- * SOMNOMED TAKES 'UPDATE, GUIDANCE' HALT TO SUSPENSION
- * GREGORY GEORGE, G TO THE FOURTH TAKE 12% OF MESOBLAST
- * CHAIR OTTO BUTTULA TAKES 14% OF RHYTHM
- * GZ FAMILY TAKES 5% OF FIREBRICK
- * CHAIR ALAN TRIBE, AUSTRALIAN LAND TAKE 36% OF PYC
- * NEUROSCIENTIFIC APPOINTS DIRECTOR DR TONY KEATING EXECUTIVE
- * ECHO IQ LOSES CEO KIMBER ROTHWELL, CHAIR ANDREW GROVER INTERIM
- * OPTISCAN APPOINTS KEN LOCK, NICOLE WILLIAMS US OPERATIONS
- * CLEO APPOINTS HCFOCUS US MARKET ACCESS CONSULTANT

MARKET REPORT

The Australian stock market fell 0.11 percent on Tuesday April 2, 2024, with the ASX200 down 9.0 points to 7,887.9 points. Eighteen of the Biotech Daily Top 40 stocks were up, 19 were down and three traded unchanged. All three Big Caps fell.

Mesoblast was the best for the second trading day in a row. The company closed at 55 cents on Easter Thursday but climbed in the US on Thursday and Monday to \$US6.08, equivalent to 93.7 cents per Australian share. Today, Mesoblast closed up 39.5 cents or 71.2 percent at 95 cents, with 86.1 million shares traded.

Clinuvel and Resonance climbed more than eight percent; Next Science was up 7.7 percent; Imugene, Medical Developments, Nova Eye and Starpharma improved four percent or more; Immutep rose 2.6 percent; Clarity, Nanosonics, Neuren, Opthea, Paradigm, Percheron, Pro Medicus and SDI were up one percent or more; with Proteomics up by 0.9 percent.

Alcidion led the falls, down 0.4 cents or 7.8 percent to 4.7 cents, with 3.6 million shares traded, followed by Universal Biosensors down 7.5 percent to 18.5 cents, with 357,438 shares traded. Impedimed lost 6.5 percent; Micro-X and Syntara fell more than four percent; Actinogen, Avita, Dimerix, Prescient and Resmed were down more than three percent; Curvebeam, Cynata, Polynovo and Telix shed more than two percent; Orthocell was down 1.3 percent; with 4D Medical, Cochlear, CSL, Cyclopharm, Emvision, Genetic Signatures and Volpara down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

March was another stellar, record-breaking month for the Biotech Daily Top 40 Index (BDI-40) with 24 companies up, of which 12 were up by more than 10 percent, with Mesoblast more than doubling to \$633 million and Dimerix up 68.4 percent to \$165 million. Fifteen companies fell and one was unchanged.

The BDI-40 was up 2.9 percent for the month to a record collective market capitalization of \$27,200 million, and up 39.6 percent for the year, while the benchmark ASX200 was up 2.6 percent in March to 7,897 points and up 10.0 percent for the year to March 31, 2024.

The Nasdaq Biotechnology Index (NBI) edged up one point or 0.02 percent for the month to 4,430 points and up 7.4 percent for the year.

The Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) recovered in March, up 2.5 to a collective market capitalization of \$205,529 million, and up 2.5 percent for the year to March 31, 2024. The three Big Caps record high was \$215,852 million on August 31, 2021 (see charts below). Resmed did the heavy lifting in March, up 12.9 percent to \$44,285 million, with CSL up 0.6 percent to \$139,138 million, while Cochlear shed 3.6 percent to \$22,106 million.

Mesoblast was March's best, on news that the US Food and Drug Administration would accept more data from its 2018 paediatric graft versus host disease trial for a biologics licence application, recovering \$333 million or 110.0 percent to \$633 million.


Mesoblast was followed up by Dimerix (68.4%), Universal Biosensors (35.3%), Emvision (25.7%), Resonance (24.0%), Genetic Signatures (22.1%), Nova Eye (17.8%), Prescient (15.8%), Opthea (15.6%), Atomo (11.1%), Proteomics (11.0%), Impedimed (10.7%) and Neuren adding \$240 million to the index - up 9.7 percent.

Medical Developments led the falls, down \$19 million or 26.8 percent to \$52 million, followed by Compumedics (17.2%), Imugene (shedding \$110 million or 12.5%), Orthocell (7.9%), Syntara (7.4%), Starpharma (7.1%), Clarity (5.5%) and Avita (4.7%).


The 11-member Cannabis Corner climbed 13.75 percent from a very low base in March to a collective market capitalization of \$374 million, down 22.3 percent for the year. Seven were up, one fell and three were unchanged. Avecho was the best, up 60 percent to \$16 million, followed by Emyria up 46.7 percent to \$22 million and Vitura up 34.6 percent to \$109 million.

Outside the BDI-40, Botanix showed the value of dropping medical marijuana and “going straight”, climbing 33.1 percent to \$354 million, its record highest market capitalization. Argenica’s clinical progress has been rewarded with the market cap more than doubling over the year from \$29 million at March 31, 2023 to \$67 million at March 31, 2024. Similarly, Neurotech’s marijuana for autism trial expansion has pushed it up 114.9 percent to \$101 million, with Immuron up 52.9 percent to \$26 million. Pharmaust was up 322.9 percent to \$148 million – watch this Monepantel for motor neuron disease (MND) space.

BDI-40 v ASX200 Jun 30, 2006 to Mar 31, 2024- Adjusted



Big Caps \$m (Cochlear, CSL, Resmed) Mar 31, 2019 – Mar 31, 2024



AEGROS

Aegros chief executive officer John Manusu says that the plasma fractionator hopes to raise \$100 million at \$18.00 a share “in the near term”.

Mr Manusu told Biotech Daily that the funds would be used to complete the \$65 million Sydney manufacturing plant for its hyperimmune products, including its first intended product for Covid-19.

Mr Manusu said that he expected the factory to be able to produce “\$600 million worth of product” a year.

“That’s not an insignificant enterprise,” Mr Manusu said.

Mr Manusu said that currently he and founding chair Hari Nair and “friends and family” held about 60 percent of the company, which had 720 individual shareholders.

According to STK Markets, “Aegros has developed the Haemafrac machine and process which will disrupt the industry”.

“It produces higher yields, from smaller batch sizes, and is significantly faster,” STK Markets said.

The company said that Haemafrac significantly reduces cost of goods, with double the yield.

Mr Manusu said that interested investors should contact Sean Sandilands at STK Markets by emailing: sean@stkmarkets.com.

Aegros is a public unlisted company

IMRICOR MEDICAL SYSTEMS

Imricor says it has placed the about \$6.47 million shortfall from its entitlement offer at 45 cents per Chess depository interest (CDI), taking the total raised to \$15 million.

In February, Imricor said it had raised \$8.0 million through placements and an institutional rights offer at 45.0 cents per CDI; and later said it had raised \$638,581 in a retail rights offer (BD: Feb 5, 27, 2024).

Imricor fell 2.5 cents or 4.5 percent to 53.5 cents.

RESONANCE HEALTH

Resonance says it will acquire Perth’s clinical trial and research centre Trialswest Pty Ltd for \$4 million in up-front cash and a further \$4 million in an earnout arrangement.

Resonance said Trialswest was “one of Australia’s most experienced and successful clinical research centres having partnered with some of the world’s leading pharmaceutical and biotechnology companies”.

The company said it expected the acquisition to contribute \$2 million in revenue and \$670,000 in earnings before interest, taxes, depreciation and amortization (Ebitda) a year.

Resonance said the \$4 million earnout payment was subject to financial milestones to 2026, and that the transaction was expected to be completed by July, 2024.

The company said Trialswest’s founders Dr Helen Pavitt, Michelle Davies and Prof Peter Bremner would remain in their roles at Trialswest for “at least the next three years”.

Resonance said the purchase would be funded by cash reserves and a “new debt facility”.

Resonance chief executive officer Andrew Harrison said the company was “delighted to be welcoming Trialswest into the Resonance Health family”.

“Trialswest has built a truly great business and its contributions to the Resonance will be highly valued, both with respect to work already underway and for future clinical trial work for our expanding base of global pharmaceutical customers,” Mr Harrison said.

Resonance was up 0.6 cents or 8.6 percent to 7.6 cents.

COGSTATE

Cogstate says it has amended its licence with Tokyo's Eisai Co Ltd to re-acquire the rights to its products in exchange for a \$15 million reduction in future royalties.

Last year, Cogstate chief executive officer Brad O'Connor told Biotech Daily that the company had a 50-50 revenue and profit share agreement with Eisai from 2019 and in 2020 launched Nouknow for brain health (BD Aug 28, 2019; Mar 23, 2020; Sep 28, 2023).

Today, the company said it retained its initial upfront payment of \$15 million, \$3.5 million in royalties to date and was eligible for minimum royalties of \$11.5 million until 2031.

Cogstate said Eisai was granted a non-exclusive licence for Cognigram in the US and Cogmate in certain Asian countries until August 2031.

Cogstate fell seven cents or 5.2 percent to \$1.28.

CENTENARY INSTITUTE

The Centenary Institute says it has received a \$199,816, two-year grant from Cancer Australia to research chemotherapy resistance in ovarian cancer patients.

The Institute said the grant was from Cancer Australia's Collaborative Cancer Research scheme and was co-funded by the Ovarian Cancer Research Foundation.

The Centenary Institute said the research would be led by Dr Alex Cole and would develop treatments to counteract a protein called follistatin which was known for making ovarian cancer cells chemotherapy resistant.

The Institute said the research aimed to create nanobodies that could block follistatin and enhance the effectiveness of chemotherapy in treating ovarian cancer.

Dr Cole said that chemotherapy triggered increased follistatin production, aiding cancer resistance.

"Our nanobodies, derived from antibodies and engineered to target and neutralize [follistatin], could potentially make cancer cells vulnerable to chemotherapy again," Dr Cole said.

UNIVERSITY OF QUEENSLAND

The University of Queensland says "targeting amyloid plaque is not essential for ultrasound to deliver cognitive improvement in neuro-degenerative disorders" in mice.

A media release from the University said previous studies of ultrasound for Alzheimer's disease had focused on opening the blood-brain barrier with micro-bubbles, which activated microglia and cleared the brain of amyloid plaque.

The University of Queensland said that its researchers used scanning ultrasound without micro-bubbles on mice and found it could "induce long-lasting cognitive changes in the brain, correlating with memory improvement".

The University said the study found the effectiveness of the ultrasound therapy varied depending on the frequency used and that researchers hoped to include the findings into a safety trial of non-invasive ultrasound for Alzheimer's disease.

The University said the research paper, titled 'Scanning ultrasound-mediated memory and functional improvements do not require amyloid- β reduction' was published in Molecular Psychiatry, with the full article available at: <https://bit.ly/49n5wDz>.

The University of Queensland's researcher Dr Gerhard Leinenga said "ultrasound on its own has direct effects on the neurons, with increased plasticity and improved brain networks".

"We think the ultrasound is increasing the plasticity or the resilience of the brain to the plaques, even though it's not specifically clearing them," Dr Leinenga said

[ARTRYA](#)

Artrya says the Wollongong-based Cardiac Centre New South Wales (NSW) will use its Salix coronary anatomy software for cardiovascular disease at four cardiac centres. Artrya said the 12-month agreement was its first in Australia and Cardiac Centre NSW would use its Salix coronary anatomy software “to detect vulnerable plaque in patients, the most accurate indicator of heart disease”.

The company said the Cardiac Centre NSW would use Salix at its centres in Wollongong, Shellharbour, Bowral and Nowra, which collectively treated more than 25,000 patients a year for heart disease.

Artrya said Salix provided a “full diagnostic and evidence-based assessment within 10 minutes of first scan” and would improve the diagnosis workflow of coronary artery disease and save unnecessary costs and minimize patient re-admissions.

The company said the agreement followed an evaluation of its Salix coronary anatomy software by cardiovascular imaging specialists at the Cardiac Centre NSW.

Artrya said first revenues from subscription of its software were expected by July, 2024.

Artrya chief executive officer Mathew Regan said the company expected first revenues by July following the full integration of Salix into the Cardiac Centre’s medical systems.

Artrya was up three cents or 10.2 percent to 32.5 cents.

[CARTHERICS PTY LTD](#)

Cartherics says it has an agreement to assess Ticaros Co Ltd’s Clip-Car technology in Cartherics’ induced pluripotent stem cell-derived natural killer (NK) cells.

Cartherics said the Seoul, South Korea-based Ticaros was developing clamping-based immunological synapse potentiating (Clip) chimeric antigen receptor (Car)-T cell products for solid and blood cancers.

The company said that the Clip component stabilized the immune synapse between immune cells and target tumor cells by modifying the chimeric antigen receptor, resulting in enhanced efficacy in laboratory and pre-clinical animal models.

Cartherics said the Clip-Car technology had not been assessed in natural killer cells.

The company said that each party had nominated a tumor antigen to assess and it had chosen tissue factor, while Ticaros would assess CD19 as its tumor target.

Cartherics said that pending the results, the parties would negotiate a development and commercialization agreement.

Cartherics is a private company.

[PERCHERON THERAPEUTICS \(FORMERLY ANTISENSE THERAPEUTICS\)](#)

Percheron says it has enrolled 34 of 45 patients, or 75.6 percent, in its phase IIb trial of ATL1102 for Duchenne muscular dystrophy, with seven more currently in screening.

Last year, the then Antisense said it had dosed the first of 45 patients in the trial of ATL1102 for non-ambulant boys with Duchenne muscular dystrophy, (BD: Jun 8, 2023).

Today, the company said nine patients had transitioned into the open-label extension phase of the study, and that no patients had been withdrawn from the trial, with adverse events “generally minor in severity and consistent with prior clinical experience”.

Percheron chief executive officer Dr James Garner said it was “disappointing that we still have a few more patients to enrol, but our priority is naturally to ensure that all patients meet the strict eligibility criteria and that the study is conducted exactly in accordance with the protocol,” Dr Garner said.

Percheron was up 0.1 cents or 1.2 percent to 8.4 cents.

CARDIEX

Cardiex says it has completed its biomarker wearable sensors validation study and the US Patents and Trademarks Office has awarded a patent for its Conneqt Band.

Cardiex said the validation study aimed to show its Sphygmocor biomarker technology could be used in wearable sensors to extract vascular biomarkers that could previously only be achieved using its Xcel and Pulse biometric monitors.

The company said the study showed that its Xcel monitor could be “ported into a wearable device in a format compatible with commonly used wearable sensor devices”.

Cardiex said completing the study was a “key step for the company as it prepares to lodge its [US Food and Drug Administration submission for clearance of its Conneqt Band wearable technology”, expected by October, 2024.

The company said the Conneqt Band patent was titled ‘Wearable device with photoplethysmogram sensor’.

Cardiex chief executive officer Craig Cooper said the company’s focus would “continue to be on developing and deploying medical grade biomarkers which can be used by both consumers, and importantly, clinicians, to better understand and prevent vascular disease”.

“Currently, there is not a single wearable that is medically validated for use for monitoring vascular disease in the US,” Mr Cooper said.

“This is the opportunity that we are pursuing, and which is supported by our 20 plus years of experience, patent portfolio, and validation studies on our wearable technology,” Mr Cooper said.

Cardiex was up 0.3 cents or 3.95 percent to 7.9 cents.

BCAL DIAGNOSTICS

Bcal says it has been issued Australian trademarks for ‘Bcal Dx’ and ‘Breastest’ as “pharmaceutical preparations ... diagnostic tests ... [and] medical analysis services”.

Bcal said it had submitted trademark applications for both products in the US, the UK, Europe, China and India.

Bcal chair Jayne Shaw said the “receipt of these trademark registrations represent an important milestone in our commercial launch strategy with regards to how we are able to market our ourselves and Breastest across the healthcare landscape”.

“We can build significant brand equity in our company and our products while improving our competitive advantage amidst the competitive pharmaceutical sector,” Ms Shaw said.

“Commercial launch of Breastest in Australia remains on track for late 2024 and this milestone marks an important step as we move to the final stages of ramping up our product strategy to ensure commercial success,” Ms Shaw said.

Bcal was unchanged at 10.5 cents with 1.45 million shares traded.

PHARMAUST

Pharmaust says following consultation with the ASX it has retracted financial forecasts from “recent media coverage on Channel 7 and in the West Australian”.

Pharmaust said an article in the West Australian included a quote from chief executive officer Dr Michael Thurn that contained a targeted sales figure.

The company said the statement did “not have a reasonable basis for the targeted sales figure at this stage” and that investors should not rely on the revenue target mentioned in the article.

Pharmaust was up five cents or 13.3 percent to 42.5 cents with 1.6 million shares traded.

[MGC \(MEDICAL GRADE CANNABIS\) PHARMACEUTICALS](#)

MGC says following investor approval it has changed its name to 'Argent Biopharma' and will begin trading on the ASX under the ticker code 'RGT', effective from tomorrow. Last month, MGC said its extraordinary general meeting passed all resolutions with 99.67 percent in favor of changing its name to 'Argent Biopharma' (BD: Mar 19, 2024). MGC was up one cent or 2.4 percent to 42 cents.

[ASX, IMAGION BIOSYSTEMS, OSTEOPORE](#)

The ASX says it has suspended Imagination and Osteopore under Listing Rule 17.5 for "not lodging the relevant period report by the due date" effective from today.

Imagination last traded at 7.3 cents.

Osteopore last traded at 30 cents.

[SOMNOMED](#)

Somnomed has requested a suspension following Wednesday's trading halt "regarding a trading update and earnings guidance" (BD: Mar 27, 2024).

Trading will resume on April 5, 2024, or on an earlier announcement.

Somnomed last traded at 38.5 cents.

[MESOBLAST](#)

Gregory George and G to the Fourth Investments says they have increased their holding in Mesoblast from 116,416,795 shares (10.23%) to 136,435,560 shares (11.99%).

The Tampa, Florida-based Mr George said the single largest purchase was on March 28, 2024, of 246,335 American depository receipts, equal to 2,463,350 ordinary shares, for \$US1,238,078 (\$A1,906,118), or 50.25 US cents (77.4 Australian cents) a share.

Mesoblast was up 39.5 cents or 71.2 percent to 95 cents with 86.1 million shares traded.

[RHYTHM BIOSCIENCES](#)

Rhythm chair Otto Buttula says he has increased his substantial shareholding from 24,111,396 shares (11.10%) to 34,961,396 shares (14.21%).

The Brisbane-based Mr Buttula said that through Newfound Investments Pty Ltd and Webinvest Pty Ltd, on March 21, 2024 he bought 10,850,000 shares for \$1,085,001, or 10 cents a share, in a rights issue.

In February, Rhythm said it hoped to raise up-to \$6.6 million in a three-for-10 rights offer at 10 cents a share, with one attaching option for every two shares purchased, and Mr Buttula would underwrite the offer by more than \$1 million (BD: Feb 9, 2024).

Rhythm was up 0.1 cents or 1.05 percent to 9.6 cents.

[FIREBRICK PHARMA](#)

The Oakville, New South Wales-based GZ Family Holdings Pty Ltd says it has become substantial in Firebrick with 9,045,766 shares, or 5.06 percent.

In a substantial shareholder notice signed by director Qixin Gao, GZ said that between October 13, 2022 and March 27, 2024 it bought and sold shares, with the single largest purchase 1,526,799 shares on September 19, 2023 for \$90,131, or 5.9 cents a share.

Firebrick was up 0.4 cents or eight percent to 5.4 cents.

PYC THERAPEUTICS

PYC chair Alan Tribe said his company Australian Land has increased its substantial shareholding from 1,229,813,974 shares (32.95%) to 1,537,267,467 shares (36.32%). The Perth-based Mr Tribe and Australian Land Pty Ltd said they acquired 307,453,493 shares on March 26, 2024 in an entitlement offer for \$24,596,282, or eight cents a share. Last month, PYC said it had raised \$40 million in the institutional component of its one-for-four, entitlement offer at eight cents a share, with \$34.6 million in its retail offer to follow (BD: Mar 18, 2024).

PYC was up 0.3 cents or 3.7 percent to 8.5 cents with 2.4 million shares traded.

NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says following the resignation of chief operating officer Dougal Thring it has appointed non-executive director Dr Tony Keating as an executive director.

Last year, Neuroscientific said it appointed Dr Keating as a director, he had co-founded and led Resapp from start-up to its \$180 million acquisition by Pfizer, and prior to that had been Uniquest's director of commercial engagement (BD: Dec 5, 2023).

Today, the company said Dr Keating will be paid \$40,000 a year, in addition to \$50,000 in director's fees and short-term and long-term incentives.

Neuroscientific rose 0.8 cents or 17.0 percent to 5.5 cents with 13.8 million shares traded.

ECHO IQ

Echo IQ says chief executive officer Kimber Rothwell has "stepped down" and that chair Andrew Grover will act as interim chief executive officer, effective immediately.

Echo IQ said Mr Rothwell had resigned "by mutual agreement with the board" and thanked him for his contribution.

Echo IQ fell 4.5 cents or 30 percent to 10.5 cents with 3.2 million shares traded.

OPTISCAN IMAGING

Optiscan says it has appointed Ken Lock head of clinical affairs and Nicole Williams head of regulatory affairs, at its Rochester, Minnesota office, effective from today.

Optiscan said Mr Lock had been head of clinical affairs at AGA Medical, St Jude Medical, Boston Scientific, Stereotaxis and Occlutech.

According to his LinkedIn profile, Mr Lock held a Bachelor of Science from Minnesota's St Cloud State University.

The company said Ms Williams had been director of clinical and regulatory affairs at Sterilucent and had worked at Steris and Richard Wolf Medical Instruments.

Optiscan was up 0.3 cents or 3.95 percent to 7.9 cents.

CLEO DIAGNOSTICS

Cleo says it has appointed the New York-based Hcfocus as a consultant for its US market access program for its ovarian cancer blood test.

Last year, Cleo raised \$12 million in its initial public offer at 20 cents a share to list on the ASX to commercialize its blood tests for ovarian cancer (BD: Aug 22, 2023).

Today, the company said Hcfocus was a healthcare consultant and that it would assist it with commercializing its ovarian blood cancer test.

Cleo was up two cents or 11.8 percent to 19 cents.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT MAR 31, 2024

Company \$Am	Mar 31, 2023	Feb 29, 2024	Mar 31, 2024
Cochlear	15,199	22,934	22,106
CSL	137,716	138,281	139,138
Resmed	47,587	39,221	44,285
BDI-20			
Avita	497	658	627
Clinuvel	939	686	720
Compumedics	25	58	48
Cyclopharm	171	170	169
Cynata	40	33	34
Genetic Signatures	109	104	127
Immutep	229	434	452
Medical Developments	96	71	52
Mesoblast	704	300	633
Nanosonics	1,505	827	833
Neuren	1,704	2,465	2,705
Nova Eye	49	45	53
Opthea	341	424	490
Polynovo	1,193	1,574	1,512
Pro Medicus	6,747	10,841	10,834
SDI	100	99	101
Starpharma	188	56	52
Syntara Pharmaxis	33	27	25
Telix	2,170	4,030	4,176
Volpara	193	285	289
Second 20			
4D Medical	94	260	254
Actinogen	124	77	75
Alcidion	159	67	68
Amplia	16	15	15
Atomo	22	18	20
Clarity	195	762	724
Curvebeam	87	64	66
Dimerix	37	98	165
Emvision	105	175	220
Impedimed	187	168	186
Imugene	803	878	768
Micro-X	54	60	62
Next Science	146	92	95
Orthocell	74	89	82
Paradigm	401	123	121
Percheron ANP	60	78	75
Prescient	74	38	44
Proteomics	116	136	151
Resonance	27	25	31
Universal Biosensors	58	34	46

* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Pharmaxis, Polynovo, Telix, Volpara and non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: <https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au